Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 12 July 2018

Indication(s)

- MIRAPEXIN 0.088 mg tablets
- MIRAPEXIN 0.18 mg tablets
- MIRAPEXIN 0.35 mg tablets
- MIRAPEXIN 0.7 mg tablets
- MIRAPEXIN 1.1 mg tablets

MIRAPEXIN is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).

MIRAPEXIN is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt).



- MIRAPEXIN 0.26 mg prolonged-release tablets
- MIRAPEXIN 0.52 mg prolonged-release tablets
- MIRAPEXIN 1.05 mg prolonged-release tablets
- MIRAPEXIN 1.57 mg prolonged-release tablets
- MIRAPEXIN 2.1 mg prolonged-release tablets
- MIRAPEXIN 2.62 mg prolonged-release tablets
- MIRAPEXIN 3.15 mg prolonged-release tablets

MIRAPEXIN is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000134
Orphan designation No
Date First Approved 23-02-1998
Type Medicinal product subject to medical prescription
Marketing authorisation holder Boehringer Ingelheim International GmbH